Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer

Urology

Volumn 57, Issue 4 SUPPL. 1, 2001, Pages 220-223

  Weiss, Heidi L ^a,f   Urban, Donald A ^b   Grizzle, William E ^c   Cronin, Kathleen A ^d   Freedman, Laurence S ^e   Kelloff, Gary J ^d   Lieberman, Ronald ^d  

^a School of Public Health   (United States)

^b Alabama   (United States)

^c University of Alabama at Birmingham   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e BAR ILAN UNIVERSITY   (Israel)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FENRETINIDE; TRANSFORMING GROWTH FACTOR; TUMOR MARKER;

ARTICLE; BAYES THEOREM; BIOPSY; CHEMISTRY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MALE; METABOLISM; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSTATE; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

ANTICARCINOGENIC AGENTS; BAYES THEOREM; BIOPSY; COHORT STUDIES; DOUBLE-BLIND METHOD; FENRETINIDE; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035319763     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(00)00979-1     Document Type: Article

References (6)

1. Kelloff GJ, Johnson J R, Crowell JA, et al: Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 4: 1-10, 1995.
2. Fleming TR, and De Mets DL: Monitoring of clinical trials: issues and recommendations. Control Clin Trials 14: 183-197, 1993.
3. Freedman LS, Spiegelhalter DJ, Parmar MKB: The what, why, and how of Bayesian clinical trials monitoring. Stat Med 13: 1371-1383, 1994.
4. Cronin KA, Freedman LS, Lieberman R, et al: Bayesian monitoring of phase II trials in chemoprevention. J Clin Epidemiol 52(8): 705-711, 1999.
5. Urban DA, Myers R, Manne U, et al: Evaluation of biomarker modulation by fenretinide (4HPR) in prostate cancer patients. Eur Urol 35: 429-438, 1999.
6. Kelloff GJ, Hawk ET, Crowell JA et al: Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology 10(10): 1471-1484, 1996.